The **HER-2 by FISH (Fluorescence In Situ Hybridization)** test is a specialized diagnostic procedure used to detect **HER2 gene amplification** in cancer tissue, most commonly breast cancer. By analyzing tumor samples, this test determines whether the HER2 gene is overexpressed, which plays a crucial role in guiding targeted therapies such as trastuzumab. Healthcare professionals recommend this test to confirm HER2 status when immunohistochemistry results are equivocal, ensuring accurate diagnosis and personalized treatment planning for patients.
It helps determine whether a patient’s tumor overexpresses HER2, which influences treatment options like trastuzumab or pertuzumab.
Patients diagnosed with breast cancer or gastric cancer are often recommended this test to guide therapy.
It indicates HER2 gene amplification, suggesting the patient may benefit from HER2-targeted therapies.
It means the tumor does not overexpress HER2, so HER2-targeted therapies may not be effective.
Yes, HER2 expression may change, so repeat testing can be recommended if cancer recurs or progresses.
Certainly, FISH is considered the gold standard when immunohistochemistry (IHC) results are equivocal or borderline.
It is mainly used for breast and gastric cancers, not routinely for other cancers.
...
Didn't recieved OTP Yet? Resend OTP